TY - JOUR
T1 - Night-shift work duration and risk of colorectal cancer according to IRS1 and IRS2 expression
AU - Shi, Yan
AU - Liu, Li
AU - Hamada, Tsuyoshi
AU - Nowak, Jonathan A.
AU - Giannakis, Marios
AU - Ma, Yanan
AU - Song, Mingyang
AU - Nevo, Daniel
AU - Kosumi, Keisuke
AU - Gu, Mancang
AU - Kim, Sun A.
AU - Morikawa, Teppei
AU - Wu, Kana
AU - Sui, Jing
AU - Papantoniou, Kyriaki
AU - Wang, Molin
AU - Chan, Andrew T.
AU - Fuchs, Charles S.
AU - Meyerhardt, Jeffrey A.
AU - Giovannucci, Edward
AU - Ogino, Shuji
AU - Schernhammer, Eva S.
AU - Nishihara, Reiko
AU - Zhang, Xuehong
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: We hypothesized that the risk of colorectal cancer in night-shift workers might be different according to insulin receptor substrate status. Methods: Among 77,470 eligible women having night work assessed in the Nurses’ Health Study, we documented a total of 1,397 colorectal cancer cases, of which 304 or 308 had available data on IRS1 and IRS2, respectively. We used duplication-method Cox proportional hazards regression analysis for competing risks to calculate HRs and 95% confidence intervals (CI) for each colorectal cancer subtype. We measured tumor IRS1 or IRS2 expression by immunohistochemistry (IHC). Results: Compared with women who never worked night shifts, those working ≥15 years night shifts had a marginal trend of increased overall risk of colorectal cancer (Ptrend = 0.06; multivariable HR = 1.20; 95% CI, 0.99–1.45). Longer duration of night-shift work was associated with a higher risk of IRS2-positive tumors (multivariable HR = 2.69; 95% CI, 1.48–4.89; Ptrend = 0.001, ≥15 years night shifts vs. never) but not with IRS2-negative tumors (multivariable HR = 0.90; 95% CI, 0.54–1.51; Ptrend = 0.72; Pheterogeneity for IRS2 = 0.008). Similarly, the corresponding multivariable HRs were 1.81 for IRS1-positive tumors (95% CI, 0.94–3.48; Ptrend = 0.06) and 1.13 for IRS1-negative tumors (95% CI, 0.71–1.80; Ptrend = 0.56; Pheterogeneity for IRS1 = 0.02). Conclusions: Our molecular pathologic epidemiology data suggest a potential role of IRS in mediating carcinogenesis induced by night-shift work. Impact: Although these findings need validation, rotating night shift might increase colorectal cancer risk in women with abnormal insulin receptor pathways.
AB - Background: We hypothesized that the risk of colorectal cancer in night-shift workers might be different according to insulin receptor substrate status. Methods: Among 77,470 eligible women having night work assessed in the Nurses’ Health Study, we documented a total of 1,397 colorectal cancer cases, of which 304 or 308 had available data on IRS1 and IRS2, respectively. We used duplication-method Cox proportional hazards regression analysis for competing risks to calculate HRs and 95% confidence intervals (CI) for each colorectal cancer subtype. We measured tumor IRS1 or IRS2 expression by immunohistochemistry (IHC). Results: Compared with women who never worked night shifts, those working ≥15 years night shifts had a marginal trend of increased overall risk of colorectal cancer (Ptrend = 0.06; multivariable HR = 1.20; 95% CI, 0.99–1.45). Longer duration of night-shift work was associated with a higher risk of IRS2-positive tumors (multivariable HR = 2.69; 95% CI, 1.48–4.89; Ptrend = 0.001, ≥15 years night shifts vs. never) but not with IRS2-negative tumors (multivariable HR = 0.90; 95% CI, 0.54–1.51; Ptrend = 0.72; Pheterogeneity for IRS2 = 0.008). Similarly, the corresponding multivariable HRs were 1.81 for IRS1-positive tumors (95% CI, 0.94–3.48; Ptrend = 0.06) and 1.13 for IRS1-negative tumors (95% CI, 0.71–1.80; Ptrend = 0.56; Pheterogeneity for IRS1 = 0.02). Conclusions: Our molecular pathologic epidemiology data suggest a potential role of IRS in mediating carcinogenesis induced by night-shift work. Impact: Although these findings need validation, rotating night shift might increase colorectal cancer risk in women with abnormal insulin receptor pathways.
UR - http://www.scopus.com/inward/record.url?scp=85077930346&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-19-0325
DO - 10.1158/1055-9965.EPI-19-0325
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31666286
AN - SCOPUS:85077930346
SN - 1055-9965
VL - 29
SP - 133
EP - 140
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
ER -